The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), NVIDIA Corporation (NVDA) and Eli Lilly and Company (LLY). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Apple shares have struggled lately, with the stock down -11.9% in the year-to-date period compared to +11.4% gain for the Zacks Tech sector and the +10.1% gain for the S&P 500 index.The company is benefiting from steady iPhone sales amid stiff competition and weakness in China. Apple expects the March quarter’s revenues and iPhone revenues to be similar to that of the year-ago quarter’s figure after removing the additional $5 billion it generated due to pent-up demand for iPhone 14 and iPhone 14 Pro Max in the year-ago quarter.
Unfavorable forex is expected to hurt revenues by 2% on a year-over-year basis. For the Services segment, Apple expects a double-digit growth rate, similar to the December-end quarter. Strong adoption of Apple TV+ driven by strong content is a key catalyst.
Apple is gaining a share in PCs which is positive. Apple’s strong cash balance and shareholder-friendly approach to dividend and share repurchase is noteworthy. However, growing legal complexities have been a headwind.
(You can read the full research report on Apple here >>>)
Shares of NVIDIA have outperformed the Zacks Semiconductor – General industry over the year-to-date period (+82.5% vs. +61.1%). The company’s computing & Networking revenues are gaining from the strong growth of artificial intelligence (AI), high-performance, and accelerated computing.
The data center end-market business is likely to benefit from the growing demand for generative AI and large language models using graphic processing units (GPUs) based on NVIDIA Hopper and Ampere architectures. A surge in hyperscale demand and higher sell-ins to partners across the Gaming and ProViz end markets following the normalization of channel inventory are acting as tailwinds.
Collaborations with Mercedes-Benz and Audi are likely to advance its presence in autonomous vehicles and other automotive electronics space. However, its near-term prospects are likely to be hurt by softening IT spending amid macroeconomic headwinds.
(You can read the full research report on NVIDIA here >>>)
Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+33.7% vs. +15.6%). The company’s revenue growth is being driven by higher demand for drugs like Mounjaro, Verzenio, Jardiance Taltz, and others.
Lilly’s new FDA-approved tirzepatide medicines, diabetes drug Mounjaro, and newly launched weight loss medicine, Zepbound, are expected to be key top-line drivers. Lilly has also launched some other new products recently like Omvoh and Jaypirca. These new products are expected to drive Lilly’s top line in 2024.
Lilly is also making rapid pipeline progress in areas like obesity, diabetes, and Alzheimer’s. However, generic competition for some drugs, rising pricing pressure, and challenges in meeting strong demand for incretin products like Trulicity are some top-line headwinds.
(You can read the full research report on Eli Lilly here >>>)
Other noteworthy reports we are featuring today include Exxon Mobil Corporation (XOM), American Tower Corporation (AMT) and McKesson Corporation (MCK).More By This Author:Making Sense Of The Earnings Scenario
Top Stock Reports For Blackstone, Texas Instruments & BlackRock
Top Research Reports For Lam Research, PayPal & Trane
